(1) Background: Calcinosis of the skin mainly appears in connective tissue disorders
(dystrophic subtype). It may cause inflammation, ulceration, pain, and restricted
joint mobility. Management is difficult; sodium thiosulfate is one potential therapeutic
agent with promising data on intralesional and topical formulation for smaller calcified
lesions. There are very limited data on systemic administration. (2) Methods: A retrospective
study was conducted at our department to assess the efficacy of oral and intravenous
sodium thiosulfate in dystrophic calcinosis between 2003 and 2023. (3) Results: Seven
patients were identified, who received systemic sodium thiosulfate (intravenous or
oral). The mean duration of calcinosis at the time of administration was 3.8 ± 4 years
(range 0–11). Intravenous sodium thiosulfate was administered in doses of 12.5–25
g two or three times during one week of the month for 4.5 ± 3.9 months on average.
Orally, 1–8 g was administered daily for 29.1 ± 40.9 months on average. Four of seven
patients had a partial response (57.1%). Despite no complete response, pain, ulceration
and inflammation frequency decreased, and sodium thiosulfate prevented further progression
in responsive patients. (4) Conclusions: Based on our experience and literature data,
systemic sodium thiosulfate may be a potential adjunct therapy in calcinosis, especially
if inflamed or ulcerating.
